{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Percentage of Participants with Loco-regional recurrence.","groups":[{"description":"Cetuximab- 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients. Hydroxyurea - 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation. Fluorouracil - continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours. Radiotherapy.","id":"OG000","title":"Advanced Head and Neck Cancer"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Llocoregional Recurrence","type":"PRIMARY","unitOfMeasure":"Participants"}